Limitations of this report include its single-case nature, absence of detailed tumor microenvironment profiling (e.g., PD-L1 expression, TIL density, immune cell phenotyping), and lack of long-term follow-up data to fully assess late toxicity or sustained benefit. This evidence concerns the gene CD274 and neoplasm.